What does this research mean for the field?

Combining digital health support with GLP-1 therapy produces synergistic and greater weight loss compared to digital health alone, which itself provides clinically meaningful weight and glycemic improvements in adults with obesity. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to evaluate the independent and additive effects of digital health programs and GLP-1 RA therapy on weight management and blood glucose outcomes in adults with obesity.

June 7, 2026

1469-P: Real-World Weight Loss with Digital Health with and without GLP-1 Therapy

Key Points

This study aims to evaluate the independent and additive effects of digital health programs and GLP-1 RA therapy on weight management and blood glucose outcomes in adults with obesity.
Retrospective observational analysis of adults with BMI ≥30 kg/m² using the Dario platform for weight and blood glucose management.
Participants were categorized into three groups: digital health only, GLP-1 therapy plus digital health for ≥6 months, and GLP-1 therapy plus digital health for ≥12 months.
Weight change and blood glucose levels were assessed at 6 and 12 months.
Digital health alone resulted in a weight loss of -6.2% at 6 months and -6.4% at 12 months (p<0.05).
Combination therapy with GLP-1 plus digital health produced weight loss of -13.7% at 6 months and -14.3% at 12 months (p<0.01).
29% of GLP-1 users achieved a reduction of ≥1.0 HbA1c point at 12 months, compared to 23% of non-GLP-1 users.

Abstract

Introduction and Objective: Digital health programs increasingly support weight management and GLP-1 RA therapy, yet real-world evidence quantifying their independent and additive effects remains limited. This study leveraged data from the Dario digital health platform, integrated with diagnostic and pharmacy claims, to evaluate real-world weight loss and blood glucose outcomes among adults with obesity receiving digital health support alone versus in combination with GLP-1 therapy over 6- and 12-month follow-up periods. Methods: A retrospective observational analysis of employer members with BMI ≥30 kg/m² using Dario for blood glucose and weight management was conducted. Members were categorized into three groups: (1) digital health only, (2) GLP-1 therapy plus digital health for ≥6 months, and (3) GLP-1 therapy plus digital health for ≥12 months. Weight change (%) and blood glucose levels were assessed at 6 and 12 months. GLP-1 therapies included semaglutide, tirzepatide, and dulaglutide. Results: The study included 295 members; 22.7% had type 2 diabetes based on diagnostic claims. Digital health alone resulted in clinically meaningful weight loss (-6.2% at 6 months; -6.4% at 12 months; p0.05). Combined GLP-1 plus digital health produced greater reductions (-13.7% at 6 months cohort; -14.3% at 12 months cohort; p0.01), exceeding typical pharmacotherapy-only real-world reports. Moreover, out of total population 23% of non-GLP-1 users who measured blood glucose achieved a reduction of ≥1.0 HbA1c point at 12 months, compared with 29% of users continuing GLP-1 therapy for ≥12 months in combination with digital health support. Conclusion: Based on this observational design, digital health alone was associated with meaningful improvements in weight and glycemic control, while combination with GLP-1 therapy produced synergistic and greater weight loss, supporting digital health as a critical component of GLP-1-based obesity care. Disclosure Y.F. Hershcovitz: Employee; Current; DarioHealth Corp. O. Manejwala: Employee; Current; DarioHealth Corp. Stock/Shareholder; Current; DarioHealth Corp. R. Herzfeld: Employee; Current; DarioHealth Corp.

Bookmark

Cite This Study

Hershcovitz et al. (Fri,) studied this question.

synapsesocial.com/papers/6a250c3b7def13d035e1c4b1 https://doi.org/https://doi.org/10.2337/db26-1469-p

Bookmark